Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients

Texto completo
Autor(es):
Mostrar menos -
Avelino-Silva, Vivian I. ; Miyaji, Karina T. ; Hunt, Peter W. ; Huang, Yong ; Simoes, Marisol ; Lima, Sheila B. ; Freire, Marcos S. ; Caiaffa-Filho, Helio H. ; Hong, Marisa A. ; Costa, Dayane Alves ; Dias, Juliana Zanatta C. ; Cerqueira, Natalia B. ; Nishiya, Anna Shoko ; Sabino, Ester Cerdeira ; Sartori, Ana M. ; Kallas, Esper G.
Número total de Autores: 16
Tipo de documento: Artigo Científico
Fonte: PLoS Neglected Tropical Diseases; v. 10, n. 12 DEC 2016.
Citações Web of Science: 9
Resumo

Background HIV-infected individuals have deficient responses to Yellow Fever vaccine (YFV) and may be at higher risk for adverse events (AE). Chronic immune activation-characterized by low CD4/CD8 ratio or high indoleamine 2,3-dioxygenase-1 (IDO) activity D may influence vaccine response in this population. Methods We prospectively assessed AE, viremia by the YFV virus and YF-specific neutralizing antibodies (NAb) in HIV-infected (CD4>350) and -uninfected adults through 1 year after vaccination. The effect of HIV status on initial antibody response to YFV was measured during the first 3 months following vaccination, while the effect on persistence of antibody response was measured one year following vaccination. We explored CD4/CD8 ratio, IDO activity (plasma kynurenine/tryptophan {[}KT] ratio) and viremia by Human Pegivirus as potential predictors of NAb response to YFV among HIV-infected participants with linear mixed models. Results 12 HIV-infected and 45-uninfected participants were included in the final analysis. HIV was not significantly associated with AE, YFV viremia or NAb titers through the first 3 months following vaccination. However, HIV-infected participants had 0.32 times the NAb titers observed for HIV-uninfected participants at 1 year following YFV (95% CI 0.13 to 0.83, p = 0.021), independent of sex, age and prior vaccination. In HIV-infected participants, each 10% increase in CD4/CD8 ratio predicted a mean 21% higher post-baseline YFV Nab titer (p = 0.024). Similarly, each 10% increase in KT ratio predicted a mean 21% lower post-baseline YFV Nab titer (p = 0.009). Viremia by Human Pegivirus was not significantly associated with NAb titers. Conclusions HIV infection appears to decrease the durability of NAb responses to YFV, an effect that may be predicted by lower CD4/CD8 ratio or higher KT ratio. (AU)

Processo FAPESP: 13/05246-8 - Impacto da infecção incidente pelo gbv-c na ativação celular em pessoas que vivem com o vírus da imunodeficiência humana (hiv).
Beneficiário:Dayane Alves Costa
Modalidade de apoio: Bolsas no Brasil - Doutorado